• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.
Would you like the opportunity to explore your genetic predispositions? Genetic testing can be empowering, helping you to make informed decisions about your healthcare. But using DNA analysis to diagnose and predict certain health conditions calls for trained genetic professionals to explain complex results, answer lingering questions and provide emotional support to people, especially when they’re receiving unexpected news. Genetic counselors are an important link in this chain, but their crucial healthcare role is yet to be recognized in Belgium.
With the advancements in AI (artificial intelligence) streamlining everything from dentistry to traffic congestion, people in all professions are feeling both excited and uneasy about this increasingly prevalent technology.
ATMPs (advanced therapy medicinal products) are expected to reach a global value of 80 billion euro in 2032. While it can be tempting to try to go it alone, the fastest and most intelligent way to advance is by advancing together. The event, Advanced Therapies in Belgium, presents such an occasion, offering a space for innovative ideas and featuring speakers from the forefront of the Belgian and international ATMP innovation.
At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.
The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) is a standardized framework designed by the Observational Health Data Sciences and Informatics (OHDSI) community. This open-science community aims to improve the quality of healthcare by providing guidelines for a more harmonized approach to data science.
In a world where our health is paramount, fatty liver disease, known as metabolic dysfunction-associated steatotic liver disease (MASLD), is climbing the ranks of health concerns we can't afford to ignore. Imagine your liver, which controls over 500 vital functions, including the body's detox powerhouse, getting clogged with fat. Alarmingly, about 30% of people globally are wrestling against this silent epidemic. It's a complex disease with various risk factors, especially related to gender and sex hormonal differences, making a one-size-fits-all treatment difficult.
The number of offshore wind farms in the North Sea is exponentially increasing. Their construction responds to the urgent need to transition to green energy production and carbon neutrality. The installation of these man-made structures has a notable impact on the marine ecosystem. Some positive impacts include providing a new home for various animals, and offering shelter, food, and breeding grounds. However, there have been observations of black sediment patches in the sampled sediments near the turbine foundations, suggesting a high input of organic matter into the sediment, altering natural biogeochemical processes.
After several years of dismal market activity, 2024 is already looking up for deals in the pharmaceutical industry, with a recent flurry of billion-dollar mergers and acquisitions. Is this trend being driven by the impending loss of revenue caused by soon-to-expire blockbuster drug patents? And what does it mean for earlier-stage biotech startups?
  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.
Would you like the opportunity to explore your genetic predispositions? Genetic testing can be empowering, helping you to make informed decisions about your healthcare. But using DNA analysis to diagnose and predict certain health conditions calls for trained genetic professionals to explain complex results, answer lingering questions and provide emotional support to people, especially when they’re receiving unexpected news. Genetic counselors are an important link in this chain, but their crucial healthcare role is yet to be recognized in Belgium.
With the advancements in AI (artificial intelligence) streamlining everything from dentistry to traffic congestion, people in all professions are feeling both excited and uneasy about this increasingly prevalent technology.
ATMPs (advanced therapy medicinal products) are expected to reach a global value of 80 billion euro in 2032. While it can be tempting to try to go it alone, the fastest and most intelligent way to advance is by advancing together. The event, Advanced Therapies in Belgium, presents such an occasion, offering a space for innovative ideas and featuring speakers from the forefront of the Belgian and international ATMP innovation.
At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.
The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) is a standardized framework designed by the Observational Health Data Sciences and Informatics (OHDSI) community. This open-science community aims to improve the quality of healthcare by providing guidelines for a more harmonized approach to data science.
In a world where our health is paramount, fatty liver disease, known as metabolic dysfunction-associated steatotic liver disease (MASLD), is climbing the ranks of health concerns we can't afford to ignore. Imagine your liver, which controls over 500 vital functions, including the body's detox powerhouse, getting clogged with fat. Alarmingly, about 30% of people globally are wrestling against this silent epidemic. It's a complex disease with various risk factors, especially related to gender and sex hormonal differences, making a one-size-fits-all treatment difficult.
The number of offshore wind farms in the North Sea is exponentially increasing. Their construction responds to the urgent need to transition to green energy production and carbon neutrality. The installation of these man-made structures has a notable impact on the marine ecosystem. Some positive impacts include providing a new home for various animals, and offering shelter, food, and breeding grounds. However, there have been observations of black sediment patches in the sampled sediments near the turbine foundations, suggesting a high input of organic matter into the sediment, altering natural biogeochemical processes.
After several years of dismal market activity, 2024 is already looking up for deals in the pharmaceutical industry, with a recent flurry of billion-dollar mergers and acquisitions. Is this trend being driven by the impending loss of revenue caused by soon-to-expire blockbuster drug patents? And what does it mean for earlier-stage biotech startups?